Acronym BLUGENICS
Category
Marine Biotechnology
Title From gene to bioactive product: Exploiting marine genomics for an innovative and sustainable European blue biotechnology industry Programme FP7
Instrument (FP6)
Contact Type (FP7)
Strand (Interreg)
FP7 - Collaborative Project targeted to a Special Group (such as SMEs)
Theme (FP7)
Activity Area (FP6)
Regional Area (Interreg)
Action (COST)
KBBE – Food, Agriculture and Fisheries, and Biotechnology
Specific Programme (FP7)
Cooperation
Funding source European Coordinator Werner E.G. Müller Coordinator email NA
Coordinator institution
JGU - Johannes Gutenberg University Mainz (Germany)
Institutions involved
NA - Bioalvo - Services, Research and Development In Biotechnology SA (Portugal) ,
NA - Biotrend SA (Germany) ,
CAGS - Chinese Academy of Geological Sciences (China) ,
ETH/ITES - ETH Zurich; Institute of Terrestrial Ecosystem (Switzerland) ,
NA - Fidelta D.O.O. Za Istrazivanje i Razvoj (Croatia) ,
NA - ManRos Therapeutics (France) ,
MATIS - Matis Ltd (Iceland) ,
NA - NanotecMARIN GmbH (Germany) ,
MNHN - National Museum of Natural History (France) ,
NA - Prokazyme Ehf (Iceland) ,
RBI - Rudjer Boskovic Institute (Croatia) ,
NA - Saebyli HF (Iceland) ,
UNINA - University of Naples Federico II (Italy) ,
USTAN - University of St Andrews (United Kingdom) ,
UU - Uppsala University (Sweden) ,
Start year 2012 End year 2016 Funding (€) € 8,146,397 Website https://cordis.europa.eu/project/id/311848 Summary Marine organisms, in particular sponges and their associated microorganisms, are an inexhaustible source of novel bioactive (lead) compounds for biomedical application. Industrial exploitation of this natural resource using traditional approaches is, however, hampered, with a few exceptions, by unsolvable supply problems - despite of numerous efforts in the past. Therefore, there is, very likely, only one way: to start from the genes encoding the bioproducts, or their biosynthetic pathways, to sustainably obtain the active molecules in sufficient amounts. The aim of the presented industry-driven integrating project is to combine the knowledge in marine genomics, chemogenetics and advanced chemistry to produce recombinantly prepared novel secondary metabolite (lead) compounds and analogous from them, as well as pharmacologically active peptides, and to bring them up to the pre-clinical, and hopefully also to the clinical studies. This ambitious approach is based on breakthrough discoveries and the results of previous successful EU projects of members of the applying consortium, including European leaders (or worldwide leaders) in marine (sponge) genomics, metagenomics (polyketide synthase clusters), combinatorial biosynthesis and marine natural product chemistry/structure elucidation. This multidisciplinary project, driven by high-tech genomics-based SMEs with dedicated interest in bringing marine-biotechnology-derived products to the market, will also involve the discovery and sustainable production of bioactive molecules from hitherto unexploited extreme environments, such as hydrothermal vents and deep-sea sources, and the expression/scale-up of unique enzymes/proteins of biomedical and biotechnological interest. The molecular-biology-based strategies developed in this project for a sustainable exploitation of aquatic molecular biodiversity will further strengthen the international position and effectiveness of European (SME-based) blue biotechnology industry.
Keywords
Drug discovery;
Bioprospecting;
Genomic sequencing;
Sponge;
Bioproduct;
Bioactive compounds;
Human health;
Marine Region
76
Not associated to marine areas
0
Marine Region Map
